Amphastar Pharms Inc Company Profile

✉ Email this page to a colleague

AMPHASTAR PHARMS INC has fourteen approved drugs.

There are three US patents protecting AMPHASTAR PHARMS INC drugs.

There are seventy-six patent family members on AMPHASTAR PHARMS INC drugs in forty-one countries and seventy-three supplementary protection certificates in nine countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amphastar Pharms Inc	GLUCAGON	glucagon	INJECTABLE;INJECTION	208086-001	Dec 28, 2020		RX	No	Yes		⤷ Sign Up				⤷ Sign Up
Amphastar Pharms Inc	NEOSTIGMINE METHYLSULFATE	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	209933-002	Sep 25, 2017	AP	RX	No	No		⤷ Sign Up				⤷ Sign Up
Amphastar Pharms Inc	NEOSTIGMINE METHYLSULFATE	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	209933-001	Sep 25, 2017	AP	RX	No	No		⤷ Sign Up				⤷ Sign Up
Amphastar Pharms Inc	VASOPRESSIN	vasopressin	SOLUTION;INTRAVENOUS	211857-001	Jul 18, 2022	AP	RX	No	No		⤷ Sign Up				⤷ Sign Up
Amphastar Pharms Inc	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes	10,765,602	⤷ Sign Up	Y			⤷ Sign Up
Amphastar Pharms Inc	ENOXAPARIN SODIUM	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	208600-001	Mar 14, 2019	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Amphastar Pharms Inc	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019	6,938,798	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	250 mcg/0.5 mL, 1 mL PFS	➤ Subscribe	2012-03-30

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203431	92666	Luxembourg	⤷ Sign Up	PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
0113964	97C0037	Belgium	⤷ Sign Up	PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
2203431	CR 2015 00014	Denmark	⤷ Sign Up	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0186405	SPC/GB00/021	United Kingdom	⤷ Sign Up	PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
2203431	1590018-6	Sweden	⤷ Sign Up	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0268956	1999C0030	Belgium	⤷ Sign Up	PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.